Anavex outlines regulatory milestones for blarcamesine in 2026 while advancing ACCESS-AD participation
Source: SeekingAlpha
2026-02-09 11:16:04 ET
More on Anavex Life Sciences
- Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript
- Anavex And Alzheimer's Disease: The Future Never Seems To Be Now
- Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Anavex Life Sciences GAAP EPS of -$0.06 beats by $0.05
- Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's
Read the full article on Seeking Alpha
For further details see:
Anavex outlines regulatory milestones for blarcamesine in 2026 while advancing ACCESS-AD participation
Anavex Life Sciences Corp.
NASDAQ: AVXL
AVXL Trading
0.0% G/L:
$4.735 Last:
281,388 Volume:
$4.78 Open:
AVXL Latest News
February 25, 2026 07:30:00 am
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
February 23, 2026 07:30:00 am
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
AVXL Stock Data
$387,970,315
82,292,521
0.31%
73
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
